Current Obesity Reports, an esteemed journal published by SPRINGER, serves as a pivotal platform for scholars and practitioners in the field of obesity research. With its ISSN of 2162-4968, this journal has been recognized within the competitive landscape of Medicine & Internal Medicine, achieving a commendable Scopus rank of #11 out of 167, placing it in the top 93rd percentile. Launched in 2012 and covering critical developments in obesity up to 2024, this journal synthesizes innovative research, evidence-based practices, and comprehensive reviews that cater to a diverse audience, from researchers to public health professionals. While currently not offering open access options, it remains dedicated to advancing knowledge and fostering discussions that address the multifaceted issues related to obesity, its public health implications, and treatment methodologies. For those involved in tackling obesity challenges, Current Obesity Reports stands as a vital resource, contributing significantly to the discourse and scholarship in the field.

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, published by Springer, is a leading journal in the field of endocrinology, diabetes, and metabolism, with an impressive Q1 ranking in both categories as of 2023. With an ISSN of 1389-9155 and E-ISSN 1573-2606, this journal serves as a vital resource for researchers, clinicians, and students seeking comprehensive reviews that address the latest advancements and interdisciplinary approaches in the management of endocrine and metabolic disorders. Operating from the Netherlands, it features articles that are rigorously peer-reviewed and is notable for its significant impact factor reflected in its Scopus rankings, placing it in the top percentile of its categories. Although it does not currently offer open access, it provides critical insights applicable to both basic and clinical settings, making it indispensable for those dedicated to enhancing patient outcomes in endocrine health.

Hormones - International Journal of Endocrinology and Metabolism, published by Springer International Publishing AG, is a vital resource within the field of Endocrinology, Diabetes, and Metabolism. Since its inception in 2005, this journal has made significant contributions to the understanding of hormonal mechanisms and their implications across various medical disciplines. With a current impact factor that places it in the Q3 category for Endocrinology and the Q2 category for miscellaneous Medicine – as indicated by its Scopus rankings – it stands out as a reputable platform for cutting-edge research and clinical findings. Although it operates under a subscription model, the journal's comprehensive scope encompasses basic and applied scientific studies, making it essential reading for researchers, clinicians, and students alike. The journal is headquartered in Germany with a strong commitment to promoting scholarly communication and knowledge dissemination within its specialized fields through the year 2024 and beyond.

Diabetology, published by MDPI, is an esteemed Open Access journal dedicated to advancing research in the fields of endocrinology, diabetes, and metabolism. Launched in 2020, this journal has quickly established itself, achieving a Category Quartile ranking of Q3 in Endocrinology, Diabetes and Metabolism and Q2 in Internal Medicine as of 2023. With a commitment to disseminating high-quality research, Diabetology provides an important platform for scientists, healthcare professionals, and students to contribute to the growing body of knowledge regarding diabetes and related conditions. Operating from its headquarters in Basel, Switzerland, the journal embraces an open access model, ensuring that research is accessible worldwide, fostering collaboration and innovation in this critical area of health. As the global diabetic epidemic continues to evolve, Diabetology plays a vital role in informing and educating stakeholders through rigorous peer-reviewed articles while boosting its visibility with impressive Scopus rankings. This journal is not only a resource for current data and findings but also a hub for groundbreaking studies that strive to improve patient outcomes and inform public health policies.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, published by the Endocrine Society, stands as a premier academic journal within the field of endocrinology, diabetes, and metabolism. With a legacy spanning from 1941 to 2024, this journal is distinguished by its significant impact factor, ranking in the Q1 category across multiple related disciplines including biochemistry, clinical biochemistry, and medicine. This esteemed journal, ISSN 0021-972X and E-ISSN 1945-7197, is backed by rigorous peer review, ensuring the publication of high-quality research that contributes to the advancement of clinical practices and scientific knowledge. With a commendable Scopus ranking, positioned in the top percentile of multiple categories, JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM serves as an essential resource for researchers, professionals, and students who seek to stay informed about the latest findings and innovations in endocrine research. The journal enriches the existing body of knowledge and fosters discussion among scholars and practitioners alike, solidifying its crucial role in the ongoing discourse in endocrinology and metabolic health.

Metabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.

Lancet Diabetes & Endocrinology is a premier peer-reviewed journal, published by Elsevier Science Inc, dedicated to advancing the fields of endocrinology, diabetes, and metabolism. Established in 2013, this journal has quickly ascended to a position of notable prestige, reflected in its prestigious Q1 rank across various categories, including Endocrinology, Internal Medicine, and Diabetes & Metabolism. With an impressive impact factor and Scopus rankings placing it in the 99th percentile of its field, it serves as a vital resource for researchers, healthcare professionals, and students alike. The journal aims to disseminate high-quality research covering clinical and experimental aspects of metabolic and endocrine disorders, making it an indispensable tool for those looking to stay at the forefront of these rapidly evolving fields. With its focus on innovative depth and cutting-edge studies, Lancet Diabetes & Endocrinology continually fosters an international dialogue critical for advancements in diabetes and endocrinology.

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES is a distinguished journal published by GEORG THIEME VERLAG KG, dedicated to advancing research and understanding in the fields of endocrinology, diabetes, and metabolism. With an ISSN of 0947-7349 and an E-ISSN of 1439-3646, this journal serves as a critical platform for disseminating high-quality research findings, reviews, and clinical studies from 1983 to 2024. The journal holds an impactful position within its respective categories, notably achieving Q3 in Endocrinology and Diabetes and Metabolism, and Q2 in Internal Medicine as per the 2023 category quartiles. Additionally, it ranks in the 57th and 46th percentiles in the Scopus rankings for Internal Medicine and Endocrinology, Diabetes and Metabolism, respectively. Though not an open-access publication, the journal caters to a global audience of researchers, professionals, and students, facilitating knowledge exchange and fostering collaboration within this vital area of medical science.

Annals of Pediatric Endocrinology & Metabolism, published by the Korean Society of Pediatric Endocrinology, is a vital resource for researchers, healthcare professionals, and students in the fields of endocrinology, diabetes, and pediatric health. With its commitment to open access since 2012, the journal facilitates the dissemination of groundbreaking research on pediatric endocrine disorders and metabolic diseases, ensuring that vital knowledge is accessible to a global audience. The journal maintains a reputable standing with a 2023 Scopus rank of #92 in Pediatrics and a Q3 quartile in Endocrinology, highlighting its impact on the field. Originating from South Korea, the journal fosters a collaborative network of researchers and advocates best practices in pediatric care through interdisciplinary studies. The Annals not only enhances scientific understanding but also emphasizes practical applications aimed at improving child health outcomes, making it an essential publication for academics and practitioners alike.

DIABETES & METABOLISM, published by MASSON EDITEUR in France, is a leading academic journal dedicated to the fields of endocrinology, diabetes, and metabolism. With an impressive Impact Factor reflecting its esteemed reputation, the journal has been ranked in the Q1 category across multiple disciplines including Endocrinology, Internal Medicine, and more, showcasing its significance and influence in the scientific community. Since its inception in 1996 and continuing its contributions through 2024, DIABETES & METABOLISM systematically disseminates high-quality research findings, reviews, and clinical studies aimed at furthering knowledge and encouraging innovation in metabolic diseases. Although not an open-access journal, it ensures that valuable research is accessible to a broad audience through institutional subscriptions and affiliations. As a key resource for researchers, clinicians, and students alike, this journal stands at the forefront of advancing understanding and treatment options in diabetes and related metabolic disorders, making it an essential addition to any academic library.